A Comparative Evaluation of the Safety and Efficacy of Tegileridine and Sufentanil in Gastrointestinal Endoscopy: A Single-Center, Randomized Controlled Trial.

A Comparative Evaluation of the Safety and Efficacy of Tegileridine and Sufentanil in Gastrointestinal Endoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500114113

Enrollment

Unknown

Registered

2025-12-08

Start date

2025-12-10

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive system diseases

Interventions

Tegileridine Group:remimazolam compounded with etomidate in combination with Tegileridine?

Sufentanil Group:remimazolam compounded with etomidate in combination with sufentanil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Elective gastroscopy and colonoscopy under procedural sedation; 3. ASA I-III.

Exclusion criteria

Exclusion criteria: 1. Refusal to sign informed consent 2. Severe respiratory depression 3. Acute or severe bronchial asthma 4. Known or suspected gastrointestinal obstruction 5. Known allergy to the medications and ingredients used in this study 6. Severe hepatic, renal, and adrenal insufficiency 7. Chronic opioid use 8. Electrocardiographic examination suggestive of abnormal QT intervals 9. Chronic use of benzodiazepine drugs 10. Anticipated difficult airway.

Design outcomes

Primary

Measure	Time frame
hypoxemia;	—

Secondary

Measure	Time frame
respiratory depression;Airway interventions;Sedation/anesthesia success rate;	—

Countries

China

Contacts

Public ContactYuming Tu

Xiangyang Central Hospital

120885519@qq.com+86 183 7266 8003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026